🎯 Background & Rationale
The landmark MIST-2 trial established sequential intrapleural administration of tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) as the standard of care for complicated pleural infection, successfully reducing surgical referral rates. However, sequential administration is logistically burdensome, time-intensive, and places a heavy strain on nursing and pharmacy workflows. This study addresses whether concurrent (simultaneous) administration of tPA and DNase can improve clinical workflow and efficiency without compromising efficacy and safety compared to the gold-standard sequential protocol.
👥 Study Design & Population
- Study Type: Retrospective Cohort Study.
- Population: 210 adult patients treated with intrapleural enzyme therapy for pleural infection over an 8-year period across specific medical centers.
- Intervention (Concurrent Group): 61 patients who received concurrent administration of tPA (10 mg) and DNase (5 mg).
- Comparison (Sequential Group): 149 patients who received standard sequential administration (tPA 10 mg followed by DNase 5 mg).
- Outcome Measures: Rate of surgical referral, radiographic clearance, hospital length of stay, mortality, chest tube-related complications, and bleeding events.
📈 Methodology & Rigor
This is the largest retrospective comparison of concurrent versus sequential intrapleural enzyme therapy to date. The authors utilized detailed electronic medical record (EMR) data, prescription/dispensing logs, and discrete order sets to accurately define exposure and capture granular data on dosing schedules, administration strategies, and analgesic requirements. Prespecified sensitivity analyses were performed (e.g., adjusting for calendar year of chest tube placement and excluding early surgical cases). Limitations inherent to retrospective design remain, including potential unmeasured confounders, temporal bias due to a recent institutional shift toward exclusive concurrent dosing, lack of blinded radiographic review, and absence of standardized severity scores (like RAPID) uniformly across the cohort.
🔬 Key Findings [or Planned Endpoints]
- Surgical Referral: The concurrent administration group demonstrated a significantly lower rate of surgical referral compared to the sequential group (13% vs 30%; adjusted OR 0.30, 95% CI 0.13–0.70).
- Radiographic Clearance: Improved radiographic clearance was observed in the concurrent arm.
- Secondary Outcomes: There were no statistically significant differences between the two groups regarding overall hospital length of stay or mortality.
- Safety & Adverse Events: Concurrent delivery did not increase adverse events. Chest tube-related complications were numerically lower in the concurrent arm, and analgesic requirements were equivalent. Overall bleeding rates were low, though two patients in the concurrent arm required a blood transfusion.
⚖️ Critical Appraisal
While the observational data heavily favor the operational efficiency and potential superiority of concurrent administration, residual confounding cannot be entirely ruled out. The concurrent arm is enriched with patients from a more recent practice era, meaning improvements in general supportive care, antibiotic stewardship, or interventional radiology access may have influenced outcomes. Furthermore, radiographic endpoints were derived from qualitative radiology reports rather than blinded, standardized scoring systems. Despite these methodological limitations of retrospective data, the study successfully demonstrates that concurrent administration is safe and avoids the workflow bottlenecks of the sequential MIST-2 protocol.
💡 The Clinical Bottom Line
For the interventional pulmonologist and clinicians managing pleural infections, concurrent intrapleural tPA-DNase administration is a safe, logistically superior, and effective alternative to the traditional sequential MIST-2 protocol. It simplifies a complex nursing and pharmacy workflow by utilizing a single instillation step and a single dwell period without increasing adverse events or analgesic requirements. Until prospective, randomized controlled trials definitively confirm superiority, concurrent administration serves as a highly defensible, time-saving default strategy in clinical practice.